Avenzo Therapeutics

We’re proud to introduce Sherry Wunder, our Director, Clinical Data Management. She brings more than 25 years of experience in #oncology clinical development and has vast experience in Ph1-Ph4 #clinicaltrials. Join us in welcoming Sherry to Avenzo and learn more about her previous experience: https://lnkd.in/gH5H_svY #TeamAvenzo #NewHire #EmployeeSpotlight

At Avenzo, we are developing a pipeline of potentially best-in-class #oncology therapies to fight #cancers with high unmet medical needs. Our lead program selectively inhibits cyclin-dependent kinase 2 (CDK2), a promising target, which is dysregulated in many cancers. Learn more: https://lnkd.in/gnQQkBJY   #AvenzoScience

We are excited to introduce Denise (Leone) Trone, our new Executive Director, Biometrics at Avenzo Therapeutics. She brings more than 25 years of experience in Phase 1 through Phase 4 clinical trials and has deep expertise in #oncology clinical development. Welcome to the team, Denise!

Earlier this month, the NYSE celebrated our recent funding news with a full Trading Floor takeover! Learn more about Avenzo and follow us on our mission to develop the next generation of #oncology therapies for patients: https://avenzotx.com/news/

#ICYMI: Our CEO and Co-Founder, Athena Countouriotis MD, spoke with Kyle LaHucik of Endpoints News about our oversubscribed $150 million Series A-1 financing, which will help advance our potentially best-in-class CDK2 inhibitor, AVZO-021, expand our pipeline with additional assets, and grow our team.     Check out the Endpoints exclusive for more on this exciting news and our plans for the future: https://lnkd.in/ez-UbP2T 

We’re welcoming Stephen Huang, Ph.D., to the Avenzo team as our executive director, Clinical Biomarkers and Companion Diagnostics. Stephen has over 20 years of translational medicine and clinical biomarker development experience and will be an important asset to our team as we continue to advance our pipeline dedicated to developing #cancer therapies for patients with high unmet medical needs. Learn more about Stephen: https://lnkd.in/gH5H_svY     #TeamAvenzo #NewHire #EmployeeSpotlight 

We’re proud to welcome Shubham Chopade, Ph.D., our new executive director, CMC to the Avenzo Therapeutics team! Shubham’s extensive pharmaceutical development experience, spanning early to late phase #drugdevelopment will be invaluable to our team as we advance our mission of developing the next generation of #oncology therapies for patients. Learn more about Shubham: https://lnkd.in/gH5H_svY     #TeamAvenzo #NewHire #EmployeeSpotlight 

Join us in welcoming susan martin, senior executive assistant, to our team! Susan brings 20+ years of experience supporting C-suite executives and has previously contributed to the success of multiple organizations undergoing significant transformations, from mergers and acquisitions to high-stakes IPOs. We’re lucky to have you, Susan! Learn more about Susan: https://lnkd.in/gH5H_svY     #TeamAvenzo #NewHire #EmployeeSpotlight 

We’re excited to announce the close of a $150 million oversubscribed financing, bringing our total Series A round to $347 million raised. The funds will propel the advancement of Avenzo’s emerging #oncology pipeline, led by AVZO-021, our potentially best-in-class #CDK2 inhibitor for the treatment of HR+/HER2- metastatic breast #cancer & other advanced #solidtumors.   We are thankful for the support of this strong syndicate of healthcare investors, which enables us to pursue our bold mission of developing the next generation of oncology therapies for patients. Learn more: https://lnkd.in/gVfXu3DH   New Enterprise Associates (NEA), Deep Track Capital, Sofinnova Investments , Sands Capital, INCE Capital, 泰福资本 TF Capital, Delos Capital , Quan Capital 泉创资本 #financing  

Join us in welcoming minal M., M.B.B.S., our new vice president, Clinical Development to #TeamAvenzo! Dr. Mehta brings extensive industry experience in advancing global oncology programs with a focus on development of targeted therapies for solid tumors. We look forward to her contributions as we advance our best-in-class #oncology therapies through early and late-stage clinical development, making strides in the fight against serious #cancers. Learn more about Minal: https://lnkd.in/gH5H_svY    #TeamAvenzo #NewHire #EmployeeSpotlight